Presentation for shareholders at 73rd AGM
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech shared its FY25 results and strategy at the 73rd AGM, highlighting a strong financial turnaround after two years of post-pandemic challenges. Consolidated revenue jumped 39% to ₹481 crore from ₹347 crore in FY24, with EBITDA of ₹122 crore and net profit of ₹76 crore (versus a net loss of ₹24 crore last year). The company reduced debt by ₹36 crore during the year, grew total equity 26% to ₹359 crore, and cut non-current liabilities by half. Key operational highlights include commercial-scale production of plant-source Vitamin D3 (VITADEE Green), EU GMP and US FDA certifications for its Dahej facility, new spray-dried Vitamin D3 products for human nutrition, and a 52% stake in AGD Nutrition USA (now Fermenta USA LLC). Fermenta now serves 400+ customers across 60+ countries, with India contributing 40% of revenue and the Nutrition segment making up 86% of revenue.
The sharp rebound in revenue and profits, combined with debt reduction and a diversified global customer base, signals improving fundamentals that should support positive investor sentiment. Shareholders benefit from the company's strengthened balance sheet and clear growth runway in plant-based Vitamin D3, fortified foods, and clean-label nutrition.